Abrogation of skin disease in lupus-prone MRL/Faslpr mice by means of a novel tylophorine analog

Jin Young Choi, Wenli Gao, Tared Odegard, Her Shyong Shiah, Michael Kashgarian, Jennifer M. McNiff, David C. Baker, Yung Chi Cheng, Joseph Craft

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective. To test the therapeutic effect of DCB-3503, a synthetic compound derived from a natural product that inhibits NF-κB, on end-organ disease in the MRL-Faslpr murine model of systemic lupus erythematosus (SLE). Methods. Eight-week-old female MRI/Faslpr mice were treated intraperitoneally with a low (2 mg/kg) or high (6 mg/kg) dose of DCB-3503 for 10 weeks. Control groups were administered vehicle treatment alone (negative control) or 25 mg/kg cyclopliosphamide (positive control). Mice were bled before (8 weeks) and during (13 weeks) treatment, and when they were killed (20 weeks), and serum samples were analyzed for total IgM and IgG levels and autoantibody titers. When the mice were killed, spleen and lymph nodes (axillary, brachial, and cervical) were examined by flow cytometric analysis. The presence of skin and renal disease was determined by histopathologic analysis. Results. DCB-3503 reduced anti-double-stranded DNA and antichromatin autoantibodies and nearly abrogated inflammatory skin disease in MRL/Fas lpr mice; however, it had little effect on histologic kidney disease. Treated mice did not have hematologic or hepatic toxicity. These data indicate that end-organ disease in MRL/Faslpr mice responds differentially to NF-κB inhibitor. Conclusion. DCB-3503 causes significant abrogation of skin disease in MHL/Faslpr mice and may potentially be beneficial in the treatment of inflammatory skin disease in SLE.

Original languageEnglish
Pages (from-to)3277-3283
Number of pages7
JournalArthritis and Rheumatism
Volume54
Issue number10
DOIs
Publication statusPublished - Oct 1 2006
Externally publishedYes

Fingerprint

Skin Diseases
Systemic Lupus Erythematosus
Autoantibodies
Inbred MRL lpr Mouse
Kidney Diseases
Therapeutic Uses
Biological Products
Immunoglobulin M
tylophorine
Arm
Spleen
Immunoglobulin G
Lymph Nodes
Kidney
Control Groups
DCB 3503
Liver
DNA
Serum

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Cite this

Abrogation of skin disease in lupus-prone MRL/Faslpr mice by means of a novel tylophorine analog. / Choi, Jin Young; Gao, Wenli; Odegard, Tared; Shiah, Her Shyong; Kashgarian, Michael; McNiff, Jennifer M.; Baker, David C.; Cheng, Yung Chi; Craft, Joseph.

In: Arthritis and Rheumatism, Vol. 54, No. 10, 01.10.2006, p. 3277-3283.

Research output: Contribution to journalArticle

Choi, JY, Gao, W, Odegard, T, Shiah, HS, Kashgarian, M, McNiff, JM, Baker, DC, Cheng, YC & Craft, J 2006, 'Abrogation of skin disease in lupus-prone MRL/Faslpr mice by means of a novel tylophorine analog', Arthritis and Rheumatism, vol. 54, no. 10, pp. 3277-3283. https://doi.org/10.1002/art.22119
Choi, Jin Young ; Gao, Wenli ; Odegard, Tared ; Shiah, Her Shyong ; Kashgarian, Michael ; McNiff, Jennifer M. ; Baker, David C. ; Cheng, Yung Chi ; Craft, Joseph. / Abrogation of skin disease in lupus-prone MRL/Faslpr mice by means of a novel tylophorine analog. In: Arthritis and Rheumatism. 2006 ; Vol. 54, No. 10. pp. 3277-3283.
@article{ef8f11f7c41c4716ac41f9adbce86a44,
title = "Abrogation of skin disease in lupus-prone MRL/Faslpr mice by means of a novel tylophorine analog",
abstract = "Objective. To test the therapeutic effect of DCB-3503, a synthetic compound derived from a natural product that inhibits NF-κB, on end-organ disease in the MRL-Faslpr murine model of systemic lupus erythematosus (SLE). Methods. Eight-week-old female MRI/Faslpr mice were treated intraperitoneally with a low (2 mg/kg) or high (6 mg/kg) dose of DCB-3503 for 10 weeks. Control groups were administered vehicle treatment alone (negative control) or 25 mg/kg cyclopliosphamide (positive control). Mice were bled before (8 weeks) and during (13 weeks) treatment, and when they were killed (20 weeks), and serum samples were analyzed for total IgM and IgG levels and autoantibody titers. When the mice were killed, spleen and lymph nodes (axillary, brachial, and cervical) were examined by flow cytometric analysis. The presence of skin and renal disease was determined by histopathologic analysis. Results. DCB-3503 reduced anti-double-stranded DNA and antichromatin autoantibodies and nearly abrogated inflammatory skin disease in MRL/Fas lpr mice; however, it had little effect on histologic kidney disease. Treated mice did not have hematologic or hepatic toxicity. These data indicate that end-organ disease in MRL/Faslpr mice responds differentially to NF-κB inhibitor. Conclusion. DCB-3503 causes significant abrogation of skin disease in MHL/Faslpr mice and may potentially be beneficial in the treatment of inflammatory skin disease in SLE.",
author = "Choi, {Jin Young} and Wenli Gao and Tared Odegard and Shiah, {Her Shyong} and Michael Kashgarian and McNiff, {Jennifer M.} and Baker, {David C.} and Cheng, {Yung Chi} and Joseph Craft",
year = "2006",
month = "10",
day = "1",
doi = "10.1002/art.22119",
language = "English",
volume = "54",
pages = "3277--3283",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

TY - JOUR

T1 - Abrogation of skin disease in lupus-prone MRL/Faslpr mice by means of a novel tylophorine analog

AU - Choi, Jin Young

AU - Gao, Wenli

AU - Odegard, Tared

AU - Shiah, Her Shyong

AU - Kashgarian, Michael

AU - McNiff, Jennifer M.

AU - Baker, David C.

AU - Cheng, Yung Chi

AU - Craft, Joseph

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Objective. To test the therapeutic effect of DCB-3503, a synthetic compound derived from a natural product that inhibits NF-κB, on end-organ disease in the MRL-Faslpr murine model of systemic lupus erythematosus (SLE). Methods. Eight-week-old female MRI/Faslpr mice were treated intraperitoneally with a low (2 mg/kg) or high (6 mg/kg) dose of DCB-3503 for 10 weeks. Control groups were administered vehicle treatment alone (negative control) or 25 mg/kg cyclopliosphamide (positive control). Mice were bled before (8 weeks) and during (13 weeks) treatment, and when they were killed (20 weeks), and serum samples were analyzed for total IgM and IgG levels and autoantibody titers. When the mice were killed, spleen and lymph nodes (axillary, brachial, and cervical) were examined by flow cytometric analysis. The presence of skin and renal disease was determined by histopathologic analysis. Results. DCB-3503 reduced anti-double-stranded DNA and antichromatin autoantibodies and nearly abrogated inflammatory skin disease in MRL/Fas lpr mice; however, it had little effect on histologic kidney disease. Treated mice did not have hematologic or hepatic toxicity. These data indicate that end-organ disease in MRL/Faslpr mice responds differentially to NF-κB inhibitor. Conclusion. DCB-3503 causes significant abrogation of skin disease in MHL/Faslpr mice and may potentially be beneficial in the treatment of inflammatory skin disease in SLE.

AB - Objective. To test the therapeutic effect of DCB-3503, a synthetic compound derived from a natural product that inhibits NF-κB, on end-organ disease in the MRL-Faslpr murine model of systemic lupus erythematosus (SLE). Methods. Eight-week-old female MRI/Faslpr mice were treated intraperitoneally with a low (2 mg/kg) or high (6 mg/kg) dose of DCB-3503 for 10 weeks. Control groups were administered vehicle treatment alone (negative control) or 25 mg/kg cyclopliosphamide (positive control). Mice were bled before (8 weeks) and during (13 weeks) treatment, and when they were killed (20 weeks), and serum samples were analyzed for total IgM and IgG levels and autoantibody titers. When the mice were killed, spleen and lymph nodes (axillary, brachial, and cervical) were examined by flow cytometric analysis. The presence of skin and renal disease was determined by histopathologic analysis. Results. DCB-3503 reduced anti-double-stranded DNA and antichromatin autoantibodies and nearly abrogated inflammatory skin disease in MRL/Fas lpr mice; however, it had little effect on histologic kidney disease. Treated mice did not have hematologic or hepatic toxicity. These data indicate that end-organ disease in MRL/Faslpr mice responds differentially to NF-κB inhibitor. Conclusion. DCB-3503 causes significant abrogation of skin disease in MHL/Faslpr mice and may potentially be beneficial in the treatment of inflammatory skin disease in SLE.

UR - http://www.scopus.com/inward/record.url?scp=33750345392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750345392&partnerID=8YFLogxK

U2 - 10.1002/art.22119

DO - 10.1002/art.22119

M3 - Article

C2 - 17009262

AN - SCOPUS:33750345392

VL - 54

SP - 3277

EP - 3283

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 10

ER -